- Home
- FRME vs HCM Comparison
FRME vs HCM Comparison
Compare FRME & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRME | HCM |
|---|---|---|
| Founded | 1893 | 2000 |
| Country | United States | Hong Kong |
| Employees | 2120 | 1811 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FRME | HCM |
|---|---|---|
| Price | $39.27 | $13.72 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 4 | 1 |
| Target Price | ★ $48.33 | $13.75 |
| AVG Volume (30 Days) | ★ 402.2K | 22.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.77 | N/A |
| Revenue Next Year | $5.87 | $16.12 |
| P/E Ratio | $10.90 | ★ $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.29 | $11.51 |
| 52 Week High | $43.22 | $19.50 |
Technical Indicators
Market Signals| Indicator | FRME | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 35.78 |
| Support Level | $38.77 | $13.08 |
| Resistance Level | $39.37 | $15.49 |
| Average True Range (ATR) | 1.25 | 0.46 |
| MACD | -0.44 | -0.18 |
| Stochastic Oscillator | 23.50 | 27.73 |
Price Performance
Historical ComparisonAbout FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.